Company / PP&E (Net)
LENZ Therapeutics, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.2M
FY2025
5-year range
$54.0K / $22.6M
FY2021-FY2025
Trend
+82.6%
vs FY2024
Sector context
#151 of 193
Health Care
What the data says
LENZ Therapeutics, Inc.'s pp&e (net) of $1M is lower than 78% of companies in the Health Care sector (FY2025). Improved from $54,000 to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -4.0%.
Improved from $54,000 to $1M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -62.5%
- 5-Year CAGR
- -4.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 193This company $1.2M Sector average $777.6M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.0%, indicating a declining trend.
- In FY2025, pp&e (net) increased 82.6% year-over-year.
- Ranks #151 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2M | +82.6% |
| FY2024 | $651.0K | +1105.6% |
| FY2023 | $54.0K | -99.8% |
| FY2022 | $22.6M | +247.8% |
| FY2021 | $6.5M | +345.4% |
| FY2020 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026